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Available online 17 January 2018Immunoglobulin-A vasculitis (IgAV) is classically a childhood small-sized blood vessel vasculitis with predomi-
nant involvement of the skin. Gastrointestinal and joint manifestations are common in patients diagnosed
with this condition. Nephritis, which is more severe in adults, constitutes the most feared complication of this
vasculitis. The molecular bases underlying the origin of IgAV have not been completely elucidated. Nevertheless,
several pieces of evidence support the claim that genes play a crucial role in the pathogenesis of this disease. The
human leukocyte antigen (HLA) region is, until now, the main genetic factor associated with IgAV pathogenesis.
Besides a strong association with HLA class II alleles, specificallyHLA-DRB1 alleles, HLA class I alleles also seem to
influence on the predisposition of this disease. Other gene polymorphisms located outside the HLA region, in-
cluding those coding cytokines, chemokines, adhesionmolecules as well as those related to T-cells, aberrant gly-
cosylation of IgA1, nitric oxide production, neoangiogenesis, renin-angiotensin system and lipid, Pyrin and
homocysteine metabolism, may be implicated not only in the predisposition to IgAV but also in its severity. An
update of the current knowledge of the genetic component associated with the pathogenesis of IgAV is detailed
in this review.
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Immunoglobulin-A vasculitis (IgAV), formerly called Henoch-
Schönlein purpura, is an inflammatory vascular disease that affects
small blood vessels, predominantly capillaries, venules, or arterioles,
with IgA1-dominant immune deposits [1–12].
IgAV is classically a childhood disease [1–3, 6, 7, 9, 11–13]with an in-
cidence of about 10 cases per 100,000 a year [2, 12, 14–17]. The pediatric
form of this pathology is generally considered benign and self-limited
[2, 6, 18, 19]. In contrast, IgAV in adults is less common but often asso-
ciated with worse clinical course and outcome [1, 2, 5, 6, 12, 13, 20].
IgAV typically involves the skin and gastrointestinal (GI) tract and,
frequently, affects the joints [1–3, 5–7, 9–13, 18, 21–23]. Skin involve-
ment is considered the main clinical feature of this disease [1, 5,
11–13, 18, 22, 24, 25]. It consists of symmetric erythematous petechiae
or papules on the buttocks and lower extremities,which evolve to a typ-
ical palpable purpura [11, 24]. Other skin lesionsmay be observed in pa-
tients with this pathology [2, 11]. GI symptoms are common in IgAV [3,
5]. These manifestations encompass colicky abdominal pain that may
mimic an acute abdomen associated with nausea and vomiting [2, 3,
5, 26–28], symptoms of bowel angina and GI bleeding [1–3, 12,
28–31] manifested as melena or hematemesis sometimes with in
some cases may lead to massive hemorrhage [1, 3, 5, 28]. Joint involve-
ment includes arthralgias [1, 3, 13] or arthritis [1, 2, 28, 32] that often af-
fect knees and ankles [1, 3, 20, 28] andmay precede the development of
palpable purpura in many cases [1, 2, 16, 28, 33].
Besides the classic clinical triad mentioned above, IgAV frequently
affects kidneys [1–3, 5–7, 9–13, 18, 21–23]. Nephropathy is generally
characterized by hematuria with or without proteinuria [1, 18]. Some
cases may present severe renal involvement characterized by the pres-
ence of nephrotic or nephritic syndrome [1, 18]. Several reports have
confirmed that nephritis and especially severe renal involvement occurs
most commonly in adults [1–3, 5, 7, 9–11, 13, 18, 34]. In this regard, ne-
phritis constitutes the most serious feature of IgAV that may lead in
some cases to end-stage kidney disease [1–3, 5–7, 9–13, 18, 35, 36]. Be-
cause of that, the long-term morbidity and mortality of this pathology
are almost completely due to renal complications [1, 9, 13, 18, 34, 37].
Since the last decade of the past century, several authors have tried
to determine the mechanisms implicated in the pathogenesis of IgAV.
However, the etiology of this vasculitis has not been completely eluci-
dated [1, 3, 18, 38]. Numerous pieces of evidence support the claim
that genetics is crucial in the pathogenesis of IgAV [1, 6, 18, 38–40]. In
addition, precipitating events, such as upper respiratory tract infections
[1, 3, 5, 13, 16, 41–48] and drug intake [1–3, 5, 20, 41, 42],maymodulate
the incidence and severity of this vasculitis in those individuals geneti-
cally predisposed.
An overview of the main studies addressing the genetic background
of IgAV susceptibility and/or severity is detailed throughout this review.In addition, a concise summary of these studies is shown in Tables 1 and
2, respectively.
2. Genetics in the pathogenesis of IgAV
2.1. Overview aspects of genetics in IgAV
Genes play a key role in IgAV [5, 6, 38, 39, 40]. Significant geographic
and ethnic differences in the prevalence of this disease speak in favor of
this fact [49, 50]. Asians show a relatively higher incidence of IgAV than
Caucasian individuals [50] while black population exhibits the lowest
incidence rate of this pathology [49, 50]. In addition, the increased
IgAV risk described among first degree relatives of affected patients
[6] aswell as familial aggregation strengthen the hypothesis that genet-
ic factors are essential in the pathogenesis of this disorder [6, 51, 52].
According to these considerations, much effort has been carried out
to identify the genetic background of IgAV. Until recently, most genetic
studies performed in this field were designed as candidate gene studies
inwhich a specific polymorphism or a set of genetic variants within cer-
tain loci was genotyped. These polymorphismswere selected according
to their potential biological function or their location in a region previ-
ously reported as associatedwith the disease. Alternatively to candidate
gene studies, large-scale studies using high-throughput genotyping
techniques have become the priority approach to unravel the genetic
component of IgAV during the last years.
Overall, the results derived from these studies evidence that the ge-
netic component implicated in the pathogenesis of IgAV is complex,
probably as a result of gene–gene interactions in which the specific
role of a single gene is small.
2.2. Human leukocyte antigen (HLA) genes in IgAV
HLA region includes a group of genes located in chromosome 6
(6p21) that encode the most polymorphic human proteins, class I and
class II antigen-presenting molecules [53]. Accordingly, HLA is the
main genetic factor implicated in inflammatory immune-mediated pa-
thologies, being associated with more diseases than any other region
of the human genome [54].
In relation to the HLA class I region, the influence of HLA-B on IgAV
pathogenesis has been amatter of debate [55–60].Whereas a lack of as-
sociation of this gene with IgAV susceptibility was suggested in small
cohorts of Europeans [55, 58], a recent well-powered study revealed a
susceptibility effect of HLA-B in Caucasian patients, identifying the
HLA-B*4102 as a potential etiological allele [56]. Also, HLA-B*7, HLA-
B*15, HLA-B*35, HLA-B*40 and B*52 [60] as well as HLA-B*35, HLA-B*49
andHLA-B*50 [59] were postulated as alleles involved in IgAV predispo-
sition in Asians and Turks, respectively. Regarding IgAV severity, HLA-
B*35 was proposed as a risk allele for renal damage in small series of
Table 1
Genetic association studies assessing IgAV susceptibility.
Gene Results
HLA-B • No association [55, 58].
• HLA-B*7 ↓ susceptibility [60].
• HLA-B*15 ↑ susceptibility [60].
• HLA-B*35 ↑ susceptibility [59, 60].
• HLA-B*40 ↓ susceptibility [60].
• HLA-B*4102 ↑ susceptibility [56].
• HLA-B*49 ↓ susceptibility [59].
• HLA-B*50 ↓ susceptibility [59].
• HLA-B*52 ↑ susceptibility [60].
HLA-A • No association [58].
• HLA-A*1 ↓ susceptibility [59].
• HLA-A*2 ↑ susceptibility [59].
• HLA-A*11 ↑ susceptibility [59, 60].
• HLA-A*26 ↑ susceptibility [60].
HLA-C • No association [58].
HLA-DRB1 • No association [61, 65].
• HLA-DRB1*01 ↑ susceptibility [62–64] due to the HLA–DRB1*0103
allele [64].
• HLA-DRB1*03 ↓ susceptibility [64].
• HLA-DRB1*07 ↓ susceptibility [62, 63].
• HLA-DRB1*11 ↑ susceptibility [63].
HLA-DQA • No association [63].
• HLA-DQA1*0301 ↑ susceptibility [66].
HLA-DQB • No association [63].
C4 • Involved in IgAV susceptibility [66, 68].
TNFA • rs1800629-308 A allele ↑ susceptibility [73].
• No association of rs1800629 –308 [G/A] [74, 75].
HSPA2 • 1267 GG genotype ↑ susceptibility [73].
IL6 • No association of rs1800795 –174 [G/C] [89, 90].
• No association of rs2069827 [G/T] [90].
• No association of rs2069840 [C/G] [90].
IL6R • No association of rs2228145 [A/C] [99].
IL6ST • No association of rs2228044 [C/G] [99].
IL1ß • No association of rs16944 –511 [C/T] [105, 106].
IL1ra • No association of IL1RN*2 [112].
IL18 • rs187238 –137 G allele ↑ susceptibility [114].
• No association of rs1946518 –607 [C/] [114].
• No association of rs360719 –1297 [T/C] [114].
IFNG • No association of rs2430561 + 874 [A/T] [122].
TGFB1 • rs1800469 –509 TT genotype ↑ susceptibility [75].
MIF • No association of −173 [G/C] [132, 133].
IL8 • No association of 2767 [G/A] [136, 137].
CXCL5 • No association of rs352046 –156 [G/C] [136].
CCL5 • No association of rs2107538 –403 [G/A] [136, 141].
• No association of rs2280788 –28 [C/G] [141].
MCP1 • −2518 TT genotype and−2518 T allele ↑ susceptibility [141, 147].
SELP • −2123 GG genotype and −2123 G allele↑ susceptibility [153].
• No association of −825 [152].
SELE • No association of 561 [A/C] [156].
ICAM1 • No association of 241 R/G [160].
• No association of 469 K/E [160].
Agt • rs4762 T174M-T allele ↑ susceptibility [165].
• No association of rs699 M235T [C/T] [165, 167].
• rs699 M235T-M allele ↓ susceptibility whereas rs699 M235T-TT
genotype ↑ in adults [166].
• rs699 M235T-MT, rs699 M235T-TT and rs699 M235T-T ↑ suscep-
tibility in children [168].
AT1R • No association of 1166 [A/C] [165, 168].
ACE • No association of I16D [179].
• I6D-D ↑ susceptibility [165, 181].
• I6D-DD ↑ susceptibility [167, 182].
• I6D-ID/DD ↑ susceptibility [168].
• I6D-ID+DD ↑ susceptibility [181].
TLR2 • No association of Arg753Gln [189].
TLR4 • No association of rs4986790 896 [A/G] [189, 191].
• No association of Thr399Ile [189].
MBL • No association of rs1800450 [A/B] [195].
PTPN22 • No association of rs2476601 [G/A] (R620W) [204, 205].
• No association of rs33996649 [C/T] (R263Q) [205].
CSK • No association of rs34933034 [G/A] [205].
• No association of rs1378942 [A/C] [205].
PAX2 • No association of 1410 [C/T] [209].
• No association of 1521 [A/C] [209].
• No association of 1544 [C/T] [209].
• No association of 798 [C/T] [210].
Table 1 (continued)
Gene Results
• No association of 909 [A/C] [210].
• No association of 164 [T/A] [210].
CTLA4 • No association of 49 [A/G] [65, 227].
C1GALT1 • rs5882115 –292 DI and II genotypes ↑ susceptibility [235].
• No association of rs9639031 –734 [C/T] [235].
• No association of rs73045773 –465 [A/G] [235].
• No association of rs1008898 –330 [G/T] [235].
• No association of rs1047763 1365 [G/A] [235].
UG • No association of 38 [A/G] [242].
VEGFA • No association of rs1570360 –1154 [GA] [249].
• No association of rs2010963 –634 [G/C] [249, 250].
NOS2A • CCTTT repeat ↑ susceptibility [258].
eNOS • No association of VNTR in intron 4 [256].
• No association of 5557 [G/T] [256].
• No association of −786 [T/C] [256, 257].
• No association of 894 [G/T] [257].
• 894 T allele and GG genotype ↑ susceptibility [259].
PON1 • 192 QQ genotype ↑ susceptibility [265].
• 55 MM genotype ↓ susceptibility [265].
MEFV • M694V↑ susceptibility [269, 273, 274].
• M694V↓ susceptibility [268, 270, 271].
• E148Q ↑ susceptibility [272].
• E148Q ↓ susceptibility [269, 274].
• No association of E148Q [268, 270, 271].
• V726A ↑ susceptibility [275].
• No association of V726A [268–271, 273, 274].
• No association of M694I [268, 269, 271, 275].
• No association of K695R [268, 269, 271, 275].
• No association of M680I [268, 274].
• No association of P369S [268, 269, 272, 275].
• No association of A744S [268, 269, 273, 275].
• No association of L110P [270].
• No association of F479L [268, 269, 275].
• No association of R761H [268, 269, 275].
• No association of I692del. [268, 269, 275].
FVL • No association of 1691 [G/A] [281].
Prothrombin • No association of 20210 [G/A] [281].
MTHFR • No association of rs1801133 677 [C/T] [281, 285].
IgAV: Immunoglobulin A vasculitis; HLA: human leukocyte antigen; C4: complement com-
ponent 4; TNFA: tumor necrosis factor alpha; HSPA2: 70 kDa heat shock protein member 2;
IL6: interleukin 6; IL6R: interleukin 6 receptor; IL6ST: interleukin 6 Signal Transducer; IL1ß: in-
terleukin 1 ß; IL1ra: interleukin 1 receptor antagonist; IL18: interleukin 18; IFNG: interferon-
gamma; TGFB1: transforming growth factor beta 1; MIF: macrophage migration inhibitory
factor; IL8: interleukin 8; CXCL5: C-X-C motif chemokine 5; CCL5: chemokine (C-C motif) li-
gand 5;MCP1: chemokinemonocyte chemoattractant protein 1; SELP: selectin P; SELE: selectin
E; ICAM1: intercellular adhesion molecule 1; Agt: angiotensin; AT1R: angiotensin II receptor,
type 1; ACE: angiotensin-converting enzyme; TLR2: toll-like receptor 2; TLR4: toll-like receptor
4; MBL: mannose binding lectin; PTPN22: protein tyrosine phosphatase nonreceptor 22; CSK:
c-src tyrosine kinase; PAX2: paired box 2; CTLA4: cytotoxic T lymphocyte-associated protein 4;
C1GALT1: glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1; UG:
uteroglobin; VEGFA: vascular endothelial growth factor A; NOS2A: nitric oxide synthase 2;
eNOS: endothelial nitric oxide synthase; VNTR: variable-number tandem-repeat polymor-
phism; PON1: paraoxonase1; MEFV: mediterranean fever; FVL: factor V Leiden; MTHFR:
methylentetrahydrofolate reductase.
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HLA-B*58were related to a poor outcome in Turks [59]. By contrast, neg-
ative results regarding the severity of the disease were obtained in
Germans [58] and in the largest cohort of Caucasian patients ever
assessed for genetic studies [56].
Other genes located in the HLA class I region were tested with re-
spect to IgAV [58–60]. In this regard, whereas no implication of HLA-A
and HLA-C in the susceptibility and/or severity of the disease was
found in children from Denmark [58], HLA-A*1, HLA-A*2 and HLA-A*11
[59] aswell asHLA-A*11 andHLA-A*26 [60]were described as alleles im-
plicated in the susceptibility of IgAV in Turks and Asians, respectively. In
addition, HLA-A*1 and HLA-A*3were associated with worse clinical fea-
tures in patients from Turkey [59].
With respect to HLA class II region, different results were obtained
when HLA-DRB1 gene was evaluated in patients with IgAV [61–65]. No
relationship between this gene and the predisposition to the disease
was detected in children from India [61] and Turkey [65]. Interestingly,
Table 2
Genetic association studies assessing IgAV severity.
Gene Clinical manifestations Results
HLA-B • Age at onset, joint, GI, renal • No association [56].
• Nephritis • No association [58].
• GI and renal symptoms, RS • HLA-B*35 ↑ renal manifestations [55].
• Nephritis • HLA-B*35 ↑ nephritis [57].
• Skin, joint, GI and renal symptoms • HLA-B*44 ↑ joint involvement [59].
• Joint, GI and renal symptoms • HLA-B*56 ↑disease severity [59].
• Joint, GI and renal symptoms • HLA-B*58 ↑disease severity [59].
HLA-A • Nephritis • No association [58].
• Joint, GI and renal symptoms • HLA-A*01 ↑ disease severity [59].
• Joint, GI and renal symptoms • HLA-A*03 ↑ joint involvement [59].
HLA-C • Nephritis • No association [58].
HLA-DRB1 • GI and renal symptoms • No association [61].
• Skin, GI and renal symptoms, RS • No association [62].
• Renal symptoms • No association [63].
• Age at onset, RS and joint, GI, renal symptoms • No association [64].
• Joint, GI and renal symptoms • HLA-DRB1*13 ↑ nephrotic proteinuria [65].
HLA-DQA • Renal symptoms • No association [63].
HLA-DQB • Renal symptoms • No association [63].
TNFA • Nephritis • No association of rs1800629 –308 [G/A] [73].
• Nephritis • rs1800629 –308 GA genotype and A allele ↑ nephritis [74].
HSPA2 • Nephritis • No association of 1267 [A/G] [73].
IL6 • Nephritis, renal and GI symptoms • No association of rs1800795 –174 [G/C] [89].
• Nephritis, GI symptoms, age at onset • No association of rs1800795 –174 [G/C] [90].
• Nephritis, GI symptoms, age at onset • No association of rs2069827 [G/T] [90].
• Nephritis, GI symptoms, age at onset • No association of rs2069840 [C/G] [90].
IL6R • Nephritis, GI symptoms, age at onset • No association of rs2228145 [A/C] [99].
IL6ST • Nephritis, GI symptoms, age at onset • No association of rs2228044 [C/G] [99].
IL1ß • Joint, GI and renal symptoms, severe nephropathy, RS • rs16944 –511 T allele ↑ severe nephropathy [105].
• Age at onset, renal and GI symptoms, severe nephropathy, RS • rs16944 –511 TT genotype and T allele ↑ severe nephropathy and RS [106].
IL1ra • GI and renal symptoms, severe nephropathy, RS • ILRN*2 allele ↑ severe nephropathy and RS [112].
• Nephritis • ILRN*2 allele ↑ nephritis [113].
IL18 • Nephritis, GI symptoms • No association of rs187238 –137 [G/C] [114].
• Nephritis, GI symptoms • No association of rs1946518 –607 [C/] [114].
• Nephritis, GI symptoms • No association of rs360719 –1297 [T/C] [114].
IFNG • Nephritis • No association of rs2430561 +874 [A/T] [122].
TGFB1 • Renal symptoms • rs1800469–509 TT genotype↑ renal complications [75].
MIF • Nephritis, GI symptoms, RS • No association of −173 [G/C] [132].
• Nephritis, GI and joint symptoms • No association of −173 [G/C] [133].
IL8 • GI and renal symptoms, RS • 2767 A allele ↑ renal manifestations [136].
• Renal symptoms, RS • 2767 A allele ↑ renal manifestations [137].
CXCL5 • GI and renal symptoms, RS • No association of rs352046 –156 [G/C] [136].
CCL5 • GI and renal symptoms, RS • No association of rs2107538 –403 [G/A] [136].
• GI and renal symptoms • rs2107538 –403 TC and TT genotype ↑ renal manifestations [141].
• GI and renal symptoms • No association of rs2280788 –28 [C/G] [141].
MCP1 • GI and renal symptoms • No association of −2518 [141].
• Skin, GI and joint symptoms • -2518TT ↑ skin lesions, GI complications and joint pain [147].
SELP • Nephritis • −825 AA genotype and −825 A allele ↑ renal symptoms [152].
• Nephritis • No association of −2123 [153].
SELE • Nephritis • No association of 561 [A/C] [156].
ICAM1 • GI and renal symptoms, RS • No association of 241 R/G [160].
• GI and renal symptoms, RS • 469 K/E ↑GI manifestations [160].
Agt • Joint, GI and renal symptoms • rs4762 T174M-T allele ↑ joint and GI symptoms [165].
• Joint, GI and renal symptoms • rs699 M235T-T allele ↓ severe renal damage [165] .
• Renal symptoms • rs699 M235T-TT and rs699 M235T-T ↑ nephritis [168].
• Nephritis • No association of rs699 M235T [C/T] [166].
• Joint, GI and renal symptoms • No association of rs699 M235T [C/T] [167].
AT1R • Joint, GI and renal symptoms • No association of 1166 [A/C] [165].
• Renal symptoms • No association of 1166 [A/C] [168].
ACE • Joint, GI and renal symptoms • No association of I16D [167].
• Renal symptoms • No association of I16D [168].
• Renal symptoms • No association of I16D [180].
• Renal symptoms • I16D-DD ↑ nephritis [182].
• Renal symptoms • I16D-DD ↑ persistent proteinuria [183].
• Renal symptoms • I16D-DD ↑ nephritis [185].
• Joint, GI and renal symptoms • I16D-D ↑ severity of renal complications [165].
• Renal symptoms • I16D-D ↑ nephritis [184].
• Renal symptoms • I16D-D ↑ nephritis [186].
TLR2 • Nephritis • No association of Arg753Gln [189].
TLR4 • Nephritis • No association of rs4986790 896 [A/G] [189].
• GI and renal symptoms, RS • No association of rs4986790 896 [A/G] [191].
• Nephritis • No association of Thr399Ile [189].
PTPN22 • GI and renal symptoms, RS • No association of rs2476601 [G/A] (R620W) [204].
• Age at onset, sex and joint, GI renal symptoms • No association of rs2476601 [G/A] (R620W) [205].
• Age at onset, sex and joint, GI renal symptoms • No association of rs33996649 [C/T] (R263Q) [205].
CSK • Age at onset, sex and joint, GI renal symptoms • No association of rs34933034 [G/A] [205].
• Age at onset, sex and joint, GI renal symptoms • No association of rs1378942 [A/C] [205].
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Table 2 (continued)
Gene Clinical manifestations Results
PAX2 • Skin, joint, GI and renal symptoms • 1410 CT/1521 AC genotype ↑ renal damage [209].
• Skin, joint, GI and renal symptoms • No association of 1544 [C/T] [209].
• Age, gender, joint, GI and renal symptoms • 798 [C/T]/909 [A/C] ↑ renal manifestations [210].
• Age, gender and joint, GI, renal symptoms • No association of 164 [T/A] [210].
NPHS2 • Nephritis • No association of 954 [T/C] [218].
• Nephritis • No association of 1038 [A/G] [218].
CTLA4 • Joint, GI and renal symptoms • 49 AG genotype ↑ nephrotic proteinuria [65].
• Renal symptoms • 49 GG genotype and 49 G allele ↑ renal damage [227].
C1GALT1 • Nephritis • rs1047763 1365 GG genotype and G allele ↑ nephritis [234].
• Nephritis • No association of rs9639031 –734 [C/T] [234].
• Nephritis • No association of rs73045773 –465 [A/G] [234].
• Nephritis • No association of rs1008898 –330 [G/T] [234].
• Nephritis • No association of rs5882115 –292 [C/−] [234].
VEGFA • GI symptoms, nephritis, RS • −1154 G allele and -1154G/-634C haplotype ↑ nephritis [249].
• Nephritis • -634 CC genotype and −634 C allele ↑ nephritis [250].
NOS2A • GI symptoms, nephritis, RS • CCTTT repeat ↑ nephritis [258].
eNOS • Joint and GI symptoms, nephritis • No association of VNTR in intron 4 [256].
• Joint and GI symptoms, nephritis • No association of 5557 [G/T] [256].
• Nephritis • 894 [G/T] ↑ nephritis [257].
• Joint and GI symptoms, nephritis • No association of −786 [T/C] [256].
• Nephritis • −786 [T/C] ↑ nephritis [257].
• Meta-analysis • −786 TT genotype ↑ nephritis [259].
MEFV • Gender, age at onset, edema and joint, GI renal symptoms • M694V↑ edema, joint and GI damage [268].
• Subcutaneous edema and GI, renal, articular, urogenital, neurological,
cardiac symptoms
• M694V ↑ urogenital manifestations [269].
• Age at onset, edema, arthritis • Patients with M694V were younger and had ↑ frequency of edema and arthritis
[274].
• Gender, age at onset, edema and joint, GI, renal symptoms • E148Q ↑ edema, joint and GI symptoms [268].
• Joint and GI symptoms, nephritis • E148Q ↑ joint manifestations [272].
• Subcutaneous edema and GI, renal, articular, urogenital, neurological,
cardiac symptoms
• No association of M680I, E148Q, V726A, M694I, P369S, F479L, A744S, R761H,
I692del., K695R [269].
• Gender, age at onset, subcutaneous edema and joint, GI, renal
symptoms
• No association of M694V, E148Q, M680I, V726A, L110P [270].
• Gender, age at onset, fever, arthritis, hematuria and GI symptoms • No association of M694V, E148Q, M680I, V726A, M694I, K695R [271].
• Joint and GI symptoms, nephritis, • No association of M694V, M680I, P369S [272].
• Age at onset, edema, arthritis • No association of E148Q, M680I, V726A [274].
• Gender, age at onset, joint and GI symptoms, recurrence • No association of M694V, E148Q, M680I, V726A, M694I, P369S, F479L, R761H,
I692del., K695R [275].
FVL • Fever, gender, age at onset, arthritis, GI symptoms, hematuria • FVL allele is associated with fever [281].
Prothrombin • Fever, gender, age at onset, arthritis, GI symptoms, hematuria • No association of 20,210 [G/A] [281].
MTHFR • Fever, gender, age at onset, arthritis, GI symptoms, hematuria • rs1801133 677 TT genotype ↑ hematuria [281].
• Renal symptoms • rs1801133 677 CC genotype ↑nephritis [285].
IgAV: Immunoglobulin A vasculitis; HLA: human leukocyte antigen; GI: gastrointestinal; RS: renal sequelae; TNFA: tumor necrosis factor alpha; HSPA2: 70 kDa heat shock protein member 2;
IL6: interleukin 6; IL6R: interleukin 6 receptor; IL6ST: interleukin 6 Signal Transducer; IL1ß: interleukin 1 ß; IL1ra: interleukin 1 receptor antagonist; IL18: interleukin 18; IFNG: interferon-gamma;
TGFB1: transforming growth factor beta 1; MIF: macrophage migration inhibitory factor; IL8: interleukin 8; CXCL5: C-X-C motif chemokine 5; CCL5: chemokine (C-C motif) ligand 5; MCP1: che-
mokine monocyte chemoattractant protein 1; SELP: selectin P; SELE: selectin E; ICAM1: intercellular adhesionmolecule 1; Agt: angiotensin; AT1R: angiotensin II receptor, type 1; ACE: angiotensin-
converting enzyme; TLR2: toll-like receptor 2; TLR4: toll-like receptor 4; PTPN22: protein tyrosine phosphatase nonreceptor 22; CSK: c-src tyrosine kinase; PAX2: paired box 2; NPHS2: nephrosis 2,
idiopathic, steroid-resistant (Podocin); CTLA4: cytotoxic T lymphocyte-associated protein 4; C1GALT1: glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1; VEGFA: vascular endo-
thelial growth factor A; NOS2A: nitric oxide synthase 2; eNOS: endothelial nitric oxide synthase;VNTR: variable-number tandem-repeat polymorphism;MEFV: mediterranean fever; FVL: factor
V Leiden; MTHFR: methylentetrahydrofolate reductase.
305R. López-Mejías et al. / Autoimmunity Reviews 17 (2018) 301–315HLA-DRB1*01 [62, 63] and HLA-DRB1*11 [63] were proposed as suscep-
tibility alleles of IgAV, while HLA-DRB1*07 [62, 63] seemed to confer a
protective effect to the disease in small cohorts of Mediterranean pa-
tients. A recent well-powered cohort of Spaniards confirmed the sus-
ceptibility effect of HLA-DRB1*01 in this pathology and pointed to
DRB1*0103 as the etiological allele [64]. In addition, a potential protec-
tive role of HLA-DRB1*03was suggested [64].
With regard to the influence of HLA-class II region in disease se-
verity, including higher risk of nephritis and renal sequelae, no asso-
ciation was seen in Spaniards [61–64]. Nevertheless, HLA-DRB1*13
was suggested as a potential risk allele for nephrotic proteinuria in
Turks [65].
The potential involvement of other HLA class II genes in IgAV was
also evaluated [63, 66]. In linewith this, a potentially increased frequen-
cy of HLA-DQA1*0301 in patients with IgAV from Korea was published
[66]. However, no association between HLA-DQA and HLA-DQB and the
susceptibility and/or severity of IgAV was described in Italians [63].
Besides class I and II, HLA complex also includes the HLA class III re-
gion. Genes located in this region encode components of the comple-
ment system (like the component complement 4 [C4]), cytokines(such as tumor necrosis factor [TNF]-α) and molecules involved in im-
mune responses (including the 70 kDa heat shock proteins [Hsp70s]).
Complement system consists of a number of small proteins found in
blood [67]. These molecules enhance the ability of antibodies and
phagocytic cells to clear microbes and damaged cells from an organism,
promote inflammation and attack the pathogen's plasma membrane
[67]. Among these proteins, C4 serves a number of critical functions in
the immune response, tolerance and autoimmunity [67]. Regarding
IgAV, variations in the C4 gene were proposed as genetic risk factors
for the disease [66, 68]. Particularly, C4A*Q0 and C4B*Q0 genotypes
were associated with predisposition to IgAV [68].
TNF-α is a cytokine produced essentially by activated macrophages
[69, 70], although it can be produced bymany other cell types. Thismol-
ecule is involved in systemic inflammation, acute phase response and in
the pathogenesis of inflammatory diseases [71]. TNF-α seems to be in-
creased during the acute stage of IgAV andmay enhance the binding ac-
tivity of IgA anti-endothelial cell antibodies [72]. The potential
implication of TNFA rs1800629 –308 [G/A] polymorphism in the patho-
genesis of IgAVwas assessed [73–75]. Although a lack of association be-
tween this genetic variant and the susceptibility of the disease was
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rs1800629 –308 A allele was proposed by others [73]. Similarly, nega-
tive results were obtained when TNFA rs1800629 –308 [G/A] was eval-
uated according to IgAV severity in some studies [73] whereas an
increased risk of nephritis in patients carrying TNFA rs1800629 –308
GA genotype and TNFA rs1800629 –308 A allele was described in
some others [74].
Hsp70s are the largest and most highly conserved group of heat
shock proteins [73]. These molecules, synthesized under stress condi-
tions, are related to renal cell survival and matrix remodeling of acute
and chronic renal diseases [76]. Among these proteins, Hsp70–2 is
encoded by HSPA2 [77]. A polymorphism located in this gene (HSPA2
1267 [G/A]) was associated with immune-mediated disorders [78–80].
The potential implication of this genetic variant in the pathogenesis of
IgAV was also tested [73]. With respect to this, an increased frequency
of HSPA2 1267 GG genotype in patients with this pathology was report-
ed [73]. However, no statistically significant differences of HSPA2 1267
[G/A] genotype and allele frequencies were observed when patients
were stratified according to the presence of nephritis [73].
2.3. Non-HLA genes in IgAV
2.3.1. Cytokines genes in IgAV
Cytokines are a broad category of small proteins, produced by awide
variety of cells, which play an important role in many physiological re-
sponses including cell signaling, body growth, adiposity and hemato-
poiesis [70, 81]. These molecules are crucial in immunological
phenomena [82, 83].
One of the most relevant pro-inflammatory cytokine is interleukin
(IL)-6. This protein is produced by different cells [84] and is essential
in adaptive immunity [85]. Besides, IL-6 acts in the innate immune re-
sponse contributing to inflammatory effects [85]. A polymorphism lo-
cated at IL6 promoter, rs1800795 –174 [G/C], was related to several
inflammatory disorders [86–88]. However, no association between
this genetic variant and the susceptibility and/or severity of IgAV was
first described by Amoli et al. [89]. Afterwards, a large study, in which
the major variability of IL6 was covered by tagging, confirmed the lack
of association between IL6 rs1800795 –174 [G/C] and the pathogenesis
of the disease [90]. Additionally, data derived from this study revealed
no influence of IL6 rs2069827 [G/T] and IL6 rs2069840 [C/G] variants
on IgAV [90]. Moreover, no significant results were found when these
3 polymorphisms were combined conforming haplotypes [90].
IL-6 cytokine levels and actions appear to be partially controlled by
its receptor [91]. In this sense, IL-6 receptor is a protein complex
consisting of an IL-6 receptor subunit (IL-6R) and IL-6 signal transducer
Glycoprotein 130 (also called IL-6ST). Genetic studies evaluated the in-
fluence of IL6R rs2228145 [A/C] (that alters IL-6R levels [92]) and IL6ST
rs2228044 [C/G] variants on several inflammatory diseases [93–98]. Re-
garding IgAV, neither IL6R rs2228145 [A/C] nor IL6ST rs2228044 [C/G]
was implicated in the occurrence and/or severity of this pathology [99].
IL-1β is a pro-inflammatory pleiotropic cytokine [100] that stimu-
lates the expression of genes associated with immune responses and
increases the expression of endothelial adhesion molecules [101].
High IL-1β expression was observed in the skin biopsy specimens of
IgAV patients [102] and in the serum of individuals with nephritis
[103]. The role of IL1ß rs16944 –511 [C/T] (a polymorphism that influ-
ences IL-1ß production [104]) in the pathogenesis of IgAV was studied
[105]. Although no significant resultswere observedwhen IgAV suscep-
tibility was assessed, this genetic variant was proposed as a potential
marker of renal involvement in a small cohort of Caucasian patients
[105]. Later, a well-powered study confirmed that IL1ß rs16944 –511
TT genotype and IL1ß rs16944 –511 T allelewere related to the develop-
ment of severe renal symptoms and persistent renal damage [106].
Interleukin 1 receptor antagonist (IL-1ra), an endogenous agent that
binds to IL-1 receptor and thus competitively inhibits the binding of IL-
1ß [107], is encoded by IL1RN. A variable number tandem repeats(VNTR) polymorphism in intron 2 of this gene was characterized
[108]. The IL1RN*2 allele, that corresponds to 2 tandem repeats, was as-
sociated with lower circulating protein levels [109, 110] and the devel-
opment of autoimmune diseases [109–111]. The implication of this
variant in the pathogenesis of IgAV was analyzed [112, 113]. No rela-
tionship between IL1RN*2 and the occurrence of the disease was ob-
served [112]. Interestingly, ILRN*2 was related to nephritis [113] and
also to severe renal involvement and permanent renal damage in pa-
tients with IgAV [112].
A member of the IL-1 family cytokine that exerts a relevant pro-
inflammatory function is IL-18 [69]. This protein induces Interferon
gamma (IFN)-γ and other T-helper (Th)1 cytokines [69]. Genetic vari-
ants located at the promoter of IL18 gene, rs187238 –137 [G/C],
rs1946518 –607 [C/A] and rs360719 –1297 [T/C], were tested to deter-
mine their potential influence on the pathogenesis of IgAV [114]. The re-
sult of this assessment revealed that IL18 rs187238 –137 G allele
frequency was increased in patients compared to healthy individuals
[114]. By contrast, a lack of association between rs1946518 –607 [C/A]
and rs360719 –1297 [T/C] and the predisposition to IgAVwas observed
[114]. According to IgAV severity, no influence of these 3 genetic vari-
ants on the development of renal damage and GI symptoms was
found [114].
IFN-ϒ is a pleiotropic cytokine,member of the type II interferons [70,
115]. This molecule is involved in innate and adaptive responses [116]
by upregulating a variety of pro-inflammatory mediators [117]. Varia-
tions in the IFNG gene, especially the adenine to thymine transition at
position+874 (rs2430561), was associatedwith several rheumatic dis-
eases [118–120], including vasculitis [121]. In accordance with this
issue, the implication of IFNG rs2430561+874 [A/T] was analyzed re-
garding IgAV [122]. However, the results derived from this study did
not support a role of this genetic variant in the pathogenesis of the dis-
ease [122].
Transforming growth factor beta 1 (TGF-β1), amultifunctional cyto-
kine belonging to the TGF-β superfamily, is implicated in the modula-
tion of both immunity and inflammation [123]. Pathological
dysregulation of this molecule was implicated in the development of
immune-mediated disorders [124–126]. Some reports proposed that
TGF-β may have a role in IgAV since an increased number of TGF-β-
secreting T cells in children with acute disease was observed [127]. Be-
cause of that, a genetic variant located at TGFB1 promoter, TGFB1
rs1800469 –509 [C/T], was genotyped in patients with IgAV [75]. With
respect to this, children carrying TGFB1 rs1800469 –509 TT genotype
exhibited an increased IgAV susceptibility and also more severe clinical
presentations, in terms of renal involvement, than non-TT [75].
2.3.2. Chemokines genes in IgAV
Chemokines are a family of small secreted proteins [128] that stim-
ulate chemotaxis of cells [129]. In particular, these molecules are in-
volved in the leukocyte movement, regulating the migration of these
cells from the blood to sites of infection [128, 129]. Consequently,
chemokines are key players in immune-mediated processes [83, 130].
Themacrophagemigration inhibitory factor (MIF) is a potent activa-
tor of macrophages that inhibits the random migration of these cells,
concentrating themat the inflammatory site [69].MIF appears to be cru-
cial in vasculitides since high serum levels of this molecule were detect-
ed in patients with Wegener's granulomatosis [131]. Regarding IgAV, a
polymorphism located at MIF promoter, MIF -173 [G/C], was evaluated
[132, 133]. However, no association between this genetic variant and
the susceptibility of the disease was observed [132, 133]. It was also
the case when patients were stratified by the presence of GI complica-
tions [132, 133], nephritis [132, 133], renal sequelae [132] and joint
damage [133].
IL-8 is a chemotactic cytokine produced by macrophages and other
cell types [134]. This molecule induces chemotaxis, primarily in neutro-
phils [135]. Additionally, IL-8 also induces phagocytosis and it is in-
volved in the up-regulation and activation of integrins [135]. Case–
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morphism at position 2767 [A/G] in the 3′-untranslated region (UTR)
region of the IL8 gene and the development of IgAV [136, 137]. Howev-
er, no association between this genetic variant and the occurrence of
IgAV was reported [136, 137]. By contrast, a significantly increased fre-
quency of the IL8 2767 A allele was found in patients who developed
renal manifestations compared with patients without these complica-
tions [136, 137].
Another chemokine that stimulates the chemotaxis and homeostasis
of neutrophils is the C-X-C motif chemokine 5 (CXCL5), also known as
epithelial-derived neutrophil-activating peptide 78 (ENA-78) [83].
This protein possesses angiogenic properties [129] and is implicated in
connective tissue remodeling. A polymorphism located at CXCL5 pro-
moter, rs352046 –156 [G/C],was related to some inflammatory diseases
[138]. Because of that, this genetic variant was tested in patients with
IgAV [136]. In keeping with results obtained in giant cell arteritis
(GCA) [139] and erythema nodosum [140], no association between
CXCL5 rs352046 –156 [G/C] and the susceptibility of IgAV was observed
[136]. This was also the casewhen IgAV patients with andwithout renal
and/or severe GI manifestations were compared [136].
The regulated upon activation normal T cell expressed and secreted
(RANTES), also known as CCL5, is a chemoattractant protein, mainly for
T cells [129]. Two polymorphisms at the promoter of CCL5 gene (CCL5
rs2107538 –403 [G/A] and CCL5 rs2280788 –28 [C/G]) were analyzed
regarding the pathogenesis of IgAV [136, 141]. A lack of association be-
tween both genetic variants and the susceptibility of the disease was
disclosed [136, 141]. Nevertheless, contradictory results were obtained
when IgAV severity was evaluated [136, 141]. Whereas CCL5
rs2107538 –403 [G/A] [136] and CCL5 rs2280788 –28 [C/G] [141] did
not seem to be associated with renal and GI manifestations in different
studies, CCL5 rs2107538 –403 TC and TT genotypes were proposed as
markers of renal damage in children from China [141].
Monocyte chemoattractant protein-1 (MCP-1/CCL2) is a strong
chemoattractant for monocytes/macrophages [142, 143] and displays
chemotactic activity, also for basophils. MCP-1 is present in urine of pa-
tients with glomerular diseases and its levels correlate with the amount
of proteinuria and degree of inflammatory cell infiltration [144–146].
The implication of MCP1 –2518 [T/C] in the pathogenesis of IgAV
was assessed [141, 147]. Whereas MCP1 –2518 TT genotype and
MCP1 –2518 T allele were proposed as susceptibility factors for IgAV
[141, 147], the role of MCP1 –2518 [T/C] in the severity of the disease
is a contentious issue [141, 147]. In this context,MCP1 –2518 TTwas as-
sociated with skin lesions, GI involvement and joint pain in Iranian
Azeri–Turkish children [147]. However, no relationship of this polymor-
phism with renal and/or GI manifestations in Chinese children was
found [141].
2.3.3. Adhesion molecules genes in IgAV
Cell adhesion molecules are transmembrane proteins whose func-
tion is to promote adhesive interactionswith other cells or the extracel-
lular matrix [148]. These molecules play crucial roles in cell migration
and cellular activation in innate and adaptive immune mechanisms
[83, 148].
The Selectin family of cell adhesion molecules consists of three
members (P-selectin, E-selectin and L-selectin) which mediate rolling
of leukocytes along the endothelium [149].
P-selectin is implicated in the recruitment of leukocytes on the vas-
cular surface at inflammatory foci, their extravasation and the adhesion
of platelets to the endothelium [150]. Increased levels of soluble P-
selectin were detected in patients with IgAV and nephritis [151].
Based on this assumption, genetic variants located at the promoter of
P-selectin gene (SELP -825 and SELP -2123) were evaluated in IgAV
[152, 153]. In this sense, whereas SELP -2123 GG genotype and SELP
-2123 G allele were related to an increased disease predisposition
[153], no influence of SELP -825 on the susceptibility of IgAV was
found [152]. Conversely, while SELP -2123 was not associated with theseverity of IgAV [153], patients carrying SELP -825 AA genotype and
SELP -825 A allele exhibited a greater occurrence of renal involvement
[152].
E-selectin (also called ELAM-1 [endothelial leukocyte adhesion
molecule-1]) [154] is present exclusively in endothelial cells and its ex-
pression is regulated by increased transcription after stimulation by in-
flammatory cytokines [148]. This protein is encodedby SELE and a single
nucleotide polymorphism located at this gene (SELE 561 [A/C]) was de-
scribed as risk factor for the development of some inflammatory dis-
eases [155]. However, no influence of this genetic variant on the
predisposition to and/or severity of IgAV was disclosed in patients
from Northwest Spain [156].
Integrins are cell adhesion molecules expressed constitutively on
leukocytes and many other cell types [148]. Among them, intercellular
adhesion molecule 1 (ICAM-1) was described as decisive in leukocyte
firm arrest on endothelium [157].
ICAM-1 is highly expressed in the adventitialmicro-vessels and neo-
vessels within inflammatory infiltrates of patients with GCA [158]; and
changes in the concentrations of circulating soluble ICAM-1were corre-
lated with the disease activity [159]. Two genetic variants affecting
ICAM1 gene (241 R/G and 469 K/E) were genotyped in patients with
IgAV [160]. No relationship between both polymorphisms and disease
susceptibility was found [160]. Interestingly, although no association
of ICAM1 241 R/G and IgAV severity was observed, a significantly de-
creased risk of severe GI complications in those patients not carrying
the codon 469 K/E genotype was disclosed [160].
2.3.4. Renin-angiotensin system (RAS) genes in IgAV
RAS is involved in themodulation of vascular tone and possibly vas-
cular structure either directly or via various factors such as endothelin
and nitric oxide (NO), among others [161].
Angiotensin (Agt) II is a potent vasoconstrictor implicated in inflam-
mation [162–164]. Agt polymorphisms (rs4762 T174M [C/T] and rs699
M235T [C/T]) were evaluated regarding IgAV. As for Agt rs4762
T174M [C/T], T174M-T allele was related to a higher IgAV prevalence
and to the development of joint and GI manifestations [165]. Regarding
Agt rs699M235T [C/T], contradictory results were published [165–168].
Whereas a lack of association between this genetic variant and IgAV
predisposition was observed by some authors [165, 167], this polymor-
phism was described as a susceptibility factor in children [168] and
adults [166] by others. Likewise, no relationship between Agt rs699
M235 T [C/T] and IgAV severity was observed in some populations
[166, 167], while a higher risk of nephritis in children carrying M235
T-TT and M235 T-T [168] and a decreased frequency of severe renal
complications in those patients carrying M235T-T [165] was described
in some others.
Agt II shows its physiological function by binding to Agt II receptor
type 1 (AT1R) and type 2 (AT2R) [163]. The influence of a variant in
the gene encoding AT1R, corresponding to an adenine to cytosine
(A → C) transversion at nucleotide position 1166 of the mRNA se-
quence, on the pathogenesis of IgAV was assessed [165, 168]. However,
this polymorphism failed to be relevant to this disease [165, 168].
Angiotensin-converting enzyme (ACE) is the key limiting enzyme of
RASwhich influences the formation of Agt II [165].ACE gene contains an
insertion (I)/deletion (D) polymorphism within intron 16 (ACE I16D)
that involves the presence or absence of a 287 bp repeat sequence
[169, 170]. This genetic variant was studied in the context of vasculitis
[171–178] and, in particular, in the pathogenesis of IgAV [165, 167,
168, 179–186]. Different results were obtained regarding this issue
[165, 167, 168, 179–186]. ACE I16D did not seem to be related to the oc-
currence [179] and/or severity of IgAV [167, 168, 180] in some studies.
By contrast, an association of I6D-D [165, 181], I6D-DD [167, 182],
I6D-ID/DD [168] and I6D-ID+DD [181] with an increased IgAV suscep-
tibility was proposed by several authors. Also, an increased risk of renal
complications in children diagnosed with IgAV was related to I16D-D
[165, 184, 186] and I16D-DD [182, 183, 185].
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Toll-like receptors (TLRs), single membrane-spanning non-catalytic
receptors, usually expressed in sentinel cells, recognize structurally con-
served molecules derived frommicrobes [69, 70, 187]. These molecules
participate in the innate response and signal the activation of adaptive
immunity [83].
TLR2 (also designated as CD282) recognizes endogenous inflamma-
tory mediators in addition to microbial components, like lipoteichoic
acid of Gram-positive bacteria [69, 187, 188]. An influence of TLR2 753
Arginine/Glutamine polymorphism on chronic inflammatory diseases
was postulated [187]. However, no association of this genetic variant
in the susceptibility and/or severity of IgAV was reported [189].
Activation of TLR4 (also called CD284), depending on bacterial lipo-
polysaccharides of Gram-negative bacteria [187, 188], promotes the
production and release of pro-inflammatory cytokines [83]. A single nu-
cleotide polymorphism located in TLR4 gene, rs4986790 896 [A/G],
resulting in the amino acid substitution Aspartic acid/Glycine at position
299,was related to decreased susceptibility to some autoimmune disor-
ders [190]. By contrast, this genetic variant did not appear to be a genet-
ic risk factor for the predisposition to and/or severity of IgAV [189, 191].
Similarly, no relationship between the amino acid substitution Threo-
nine/Isoleucine at position 399 of TLR4 and the pathogenesis of IgAV
was observed [189].
Mannose-binding lectin (MBL) is a calcium-dependent lectin that
plays an important role in innate immunity by activating the comple-
ment [67] through theMBL associated serine protease (MASP) pathway
and phagocytosis [67, 192]. The genetic variant MBL rs1800450 [A/B]
was reported to be associatedwith a decrease ofMBL levels in the circu-
lation, causing predisposition to infectious and autoimmune diseases
[193, 194]. Regarding IgAV, a lack of association between this genetic
variant and the predisposition to the disease was published [195].
Protein tyrosine phosphatases (PTPs) are critical regulators of T cell
signal transduction [196, 197]. Among them, lymphoid-specific phos-
phatase (Lyp) is encoded by PTPN22 (protein tyrosine phosphatase
nonreceptor 22). The influence of the functional PTPN22 rs2476601 [G/
A] (R620W) and PTPN22 rs33996649 [C/T] (R263Q) polymorphisms
(related to inflammatory diseases [196–200] and vasculitis [201–203])
on IgAV was evaluated [204, 205]. In this context, no relationship be-
tween PTPN22 rs2476601 [G/A] (R620W) and the pathogenesis of the
disease was first described in a small cohort of patients [204] and, sub-
sequently, confirmed in awell-powered genetic study [205]. In addition,
a lack of association between PTPN22 rs33996649 [C/T] (R263Q) and
IgAV was reported [205]. Moreover, negative results were found when
PTPN22 rs2476601 [G/A] (R620W) and PTPN22 rs33996649 [C/T]
(R263Q) variants were tested together conforming haplotypes [205].
Lyp is expressed in lymphocyteswhere it physically associates to the
SH3 of c-src tyrosine kinase (CSK) [196]. Some studies described an as-
sociation between twowell-known genetic variants located in CSK gene
(CSK rs34933034 and CSK rs1378942) and several immune-mediated
disorders [206, 207]. However, no implication of these two polymor-
phisms in the predisposition to IgAV and/or severity of the disease
was described in the largest series of Caucasian patients ever assessed
for genetic studies [205].
Paired box 2 (PAX2) is an essential nuclear transcription factor in-
volved in the development of the human embryonic kidney [208].
PAX2 gene is expressed in the distal tubules and podocytes of IgAV chil-
dren with nephritis [209] and its expression appears to correlate with
the severity of the renal pathology [209]. Several PAX2 polymorphisms
(1410 [C/T], 1521 [A/C], 1544 [C/T], 798 [C/T], 909 [A/C] and 164 [T/A]
[209, 210]) were analyzed regarding IgAV pathogenesis. No influence
of these genetic variants on the susceptibility of the disease was found
[209, 210]. In addition, a lack of association between PAX2 1544 [C/T]
[209] and PAX2 164 [T/A] [210] and IgAV severity was described. Inter-
estingly, PAX2 1410 CT/1521 AC [209] and PAX2 798 [C/T]/PAX2 909 [A/
C] genotypes [210] were involved in the development of renal manifes-
tations in patients with IgAV.An important molecule localized on the membranes of podocyte
pedicels where it oligomerizes in lipid rafts together with nephrin to
form the filtration slits, is the Podocin [211]. Mutations in the gene
encoding podocin (NPHS2) were related to nephrotic syndrome, such
as focal segmental glomerulosclerosis or minimal change disease
[212]. In addition, the potential implication of NPHS2 polymorphisms
on IgA nephropathy (IgAN) was evaluated and contradictory results
were observed [213–217]. Regarding IgAV, no significant association
between NPHS2 954 [T/C] or NPHS2 1038 [A/G] polymorphisms and
the presence of renal damage in children diagnosed with this pathology
was disclosed [218].
Cytotoxic T lymphocyte-associated protein 4 (CTLA-4) (also known
as CD152), a protein expressed on activated T cells [219], helps to regu-
late T cells [220]. CTLA4 gene polymorphisms were associated with sev-
eral rheumatic diseases [221–223] and, in particular, with vasculitis
[224–226]. With respect to this, CTLA4 49 [A/G] was genotyped in pa-
tients with IgAV [65, 227]. No implication of this genetic variant in the
occurrence of the disease was reported [65, 227]. Nevertheless, a signif-
icant association between carriage of the CTLA4 49 AG genotype and ne-
phrotic proteinuria was described [65]. Also, CTLA4 49 GG genotype and
CTLA4 49 G allele were related to increased risk of renal damage [227].
Aberrant glycosylation of IgA1 plays a pivotal role in the pathogene-
sis of IgAV [228–231]. Core 1 synthase glycoprotein-N-
acetylgalactosamine 3-beta-galactosyltransferase 1 (also known as
C1GALT1) is an enzyme which activates the attachment of galactose to
N-acetylgalactosamine [232, 233]. The reduced activity of this molecule
could lead to aberrant glycosylation affecting, thus, the development of
IgAV [234]. Accordingly, five tagging C1GALT1 polymorphisms
(rs9639031 –734 [C/T], rs73045773 –465 [A/G], rs1008898 –330 [G/T],
rs5882115 –292 [C/−] and rs1047763 1365 [G/A]) were evaluated in
Chinese cohorts of patients with IgAV [234, 235]. As a result of these
studies, C1GALT1 rs5882115 –292 [C/−] was proposed as genetic risk
factor for developing IgAV [235]. Additionally, an increased frequency
of C1GALT1 rs1047763 1365 GG genotype and C1GALT1 rs1047763
1365 G allele in patients who exhibited nephritis compared to those
without this complication was found [234].
Uteroglobin (UG) is a steroid-inducible pleiotropic protein with im-
munomodulatory and anti-inflammatory properties [236, 237]. A po-
tential implication of this molecule in human glomerulonephritis was
suggested [238]. In fact, a genetic variant, at position +38 in exon 1 of
the UG gene (38 [A/G]) was related to rapid-progression of IgA ne-
phropathy [239–241]. However, results obtained by Eisenstein et al.
did not support a role of this polymorphism in susceptibility to child-
hood IgAV [242].
Vascular endothelial growth factor (VEGF) is described as amolecule
with pro-inflammatory, pro-atherogenic and pro-angiogenic properties
[70, 243, 244]. High expression of VEGF was reported in patients with
vasculitis [245–247] and, specifically, in children with IgAV in the
acute phase of the disease [248]. Polymorphisms within VEGFA gene
(rs2010963 –634 [G/C] [249, 250] and rs1570360 –1154 [GA] [249])
were tested regarding IgAV pathogenesis. No influence of both genetic
variants on IgAV susceptibility was disclosed [249, 250]. Interestingly,
VEGFA rs2010963 –634 CC and VEGFA rs2010963 –634 C were related
to renal damage in Chinese children [250] whereas VEGFA rs1570360
–1154 G allele and - VEGFA rs1570360 –1154 G/VEGFA rs2010963
–634 C haplotype were associated with nephritis in Spaniards [249].
The conversion of L-arginine to L-citrulline by endothelial (eNOS or
NOS3), neuronal (nNOS or NOS1) or inducible (iNOS or NOS2)
synthases leads to NO production [251]. Increased levels of this mole-
cule were detected in individuals with vasculitis [252, 253], especially
in children with acute phase IgAV [254, 255]. NOS2A and eNOS genes
were analyzed in the context of IgAV pathogenesis [256–259]. With re-
spect to NOS2A, a CCTTT repeat polymorphismwas associated with dis-
ease predisposition and nephritis presence [258]. Regarding eNOS,
different results were published [256, 257, 259]. No influence of a
VNTR polymorphism in intron 4 and eNOS 5557 [G/T] variant on IgAV
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eNOS 894 [G/T] in the occurrence of the disease was debatable [257,
259], this polymorphism was described as a marker of renal damage
[257]. Finally, eNOS -786 [T/C] was not related to IgAV predisposition
[256, 257] and its potential involvement in the severity of the disease
was controversial [256, 257, 259].
Paraoxonase1 (PON1) is a high density lipoprotein (HDL)-associated
enzyme involved in prevention of lipid peroxidation [260–262]. Re-
duced activity of this molecule was detected in patients diagnosed
with vasculitis [263]. In addition, polymorphisms in the gene coding
PON1 were related to vascular diseases [264] by influencing on the de-
velopment and progression of arterial damage. With respect to IgAV,
two PON1 polymorphisms located at coding regions, 192 Q/R and 55
L/M, were analyzed [265]. Data derived from this study exhibited a sig-
nificantly increased frequency of PON1 192 QQ and a significantly de-
creased frequency of PON1 55 MM in children with IgAV from Turkey
[265].
Mediterranean fever (MEFV) gene encodes a protein involved in the
regulation of neutrophil activity, called Pyrin [266, 267]. The potential
role ofMEFV variations in the pathogenesis of IgAVwaswidely assessed
and apparently contradictory results were obtained [268–275]. Where-
as a relationship betweenM694V [268–271, 273, 274], E148Q [269, 272,
274] andV726A [275] variantswith IgAV susceptibilitywas observed by
some authors, no influence of both E148Q [268, 270, 271] and V726A
[268–271, 273, 274] in the occurrence of the disease was observed by
others. Similarly, M694V and E148Q were described as variants in-
volved in IgAV severity in a few studies [268, 269, 272, 274] although
no implication of M694V [270–272, 275], E148Q [269–271, 274, 275]
and V726A [269–271, 274, 275] in the severity of the disease was
found in others. A lack of association between M694I, K695R, M680I,
P369S, A744S, L110P, R761H, F479L and I692del variants and predispo-
sition to [268–275] and/or severity of [269–272, 274, 275] IgAVwas also
disclosed.
Finally, several inflammatory genetic defects are associated with an
increased risk for venous thrombosis and arteriosclerosis [276–280].
The common inherited risk factors for thrombosis includemutant factor
V Leiden (FVL), prothrombin 20,210 [G/A] polymorphism and the 677 [C/
T] variant of methylenetetrahydrofolate reductase (MTHFR) [277–280].
A commonmutation at position 1691 of FVL gene, leading to an argi-
nine/glutamine substitution, conveys resistance to the stimulation of
activated protein C, resulting thus in an increased risk for thrombosis
[280]. When IgAV pathogenesis was analyzed, no association of this ge-
netic variant and the occurrence of the disease was detected [281]. In-
terestingly, an increased frequency of the FVL allele in patients who
manifested fever in the acute phase of the disease compared to those
patients without fever was disclosed [281]. However, no significant re-
sults were found when IgAV patients were stratified according to the
age of onset, gender, presence of arthritis, GI and renal manifestations
[281].
Prothrombin gene is the precursor of the serine protease thrombin, a
key enzyme involved in the processes of hemostasis and thrombosis.
Prothrombin 20,210 [G/A] polymorphism was associated with high risk
for venous thrombosis [277]. However, this genetic variant does not ap-
pear to be involved in the pathogenesis of IgAV since no significant re-
sults regarding both predisposition to and/or severity of the disease
were found [281].
MTHFR is an enzyme that catalyzes the irreversible reduction of
5,10-methylene tetrahydrofolate to 5-methyl tetrahydrofolate (the
methyl donor for the conversion of homocysteine to methionine)
[282]. Genetic variants located in MTHFR were related to decreased
MTHFR enzyme activity. The common polymorphism at codon 677 of
this gene (rs1801133 [C/T])was related to vasculitis [283, 284]. Regard-
ing IgAV, no influence of this genetic variant on the predisposition of the
disease was reported [281, 285]. Remarkably, a potential role ofMTHFR
rs1801133 [C/T] in the severity of IgAV was described [281, 285]. In this
sense, an increased MTHFR rs1801133 CC genotype frequency inchildren with IgAV and nephritis was observed [285]. In addition, ho-
mozygosity for the MTHFR rs1801133 TT genotype was associated
with hematuria [281].
2.4. High-throughput genotyping techniques for the assessment of the ge-
netic influence of IgAV: a genome-wide association study (GWAS)
As previously mentioned, large-scale studies using high-throughput
genotyping techniques have become the priority approach to unravel
the genetic component of IgAV during the last years.
Unlike candidate gene studies, in high-density polymorphism ar-
rays, hundreds of thousands of probes are arrayed on a small chip
allowing for many genetic variants to be interrogated simultaneously.
Among them, GWAS is a large-scale approach used in the genetic char-
acterization of immune-mediated diseases [286, 287]. This strategy is a
free-hypothesis genetic method [288] in which hundreds of thousands
of single-nucleotide polymorphisms located across the whole genome
can be analyzed [289].
GWAS have proven to be a powerful tool to unravel the genetic com-
ponent of complex diseases during the last decade, including primary
vasculitides [290] such as Takayasu Arteritis [291], Kawasaki
[292–294] andBehçet [295, 296] diseases aswell as antineutrophil cyto-
plasmic antibody (ANCA)-associated vasculitis (AAV) [297]. In line with
this, thefirst GWAS focused on IgAV has been recently conducted by our
group in the largest series of patients of European ancestry ever
assessed for a genetic study [298]. Interestingly, a linkage disequilibri-
um block of polymorphisms that maps to an intergenic region in HLA
class II, between HLA-DQA1 and HLA-DQB1, was strongly associated
with the susceptibility of the disease [298]. In particular, interesting p-
values were observed for the HLA-DRB1 positions 13 and 11 [298].
Moreover, a suggestive association in the HLA class I region and some
potential signals outside the HLA were related to IgAV predisposition
[298].
3. Current situation and future perspectives
Vasculitides are a heterogeneous group of diseases characterized by
a primary process of inflammation and damage of the blood vessel wall
[6, 21]. These disorders often have overlapping clinical and pathologic
manifestations [21] being difficult to distinguish among them in many
cases. Nevertheless, differences between vasculitides in molecular
terms have been described [40, 290].
As mentioned above, IgAV is a small-sized blood vessel vasculitis
[1–12, 18, 21, 24] with predominant involvement of the skin [1, 5,
11–13, 18, 22, 24, 25]. The present review article reveals the importance
of the genetic component in the pathogenesis of this condition.
Particularly relevant is the association of IgAV with the HLA class I
and class II region. Data derived from different studies do not seem to
be completely conclusive due to the limited statistical power of the
many of them or the lack of replication of the results obtained [59, 60,
65, 66]. Nevertheless, consistent conclusions were obtained in patients
from Europe in which a robust association of IgAV pathogenesis with
the HLA region [56, 62–64, 298], mainly with HLA class II alleles
[62–64, 298], was confirmed.
Susceptibility to IgAV was strongly associated with HLA-DRB1
[62–64, 298] in Europeans, mainly due to HLA-DR1*0103 [64]. In addi-
tion, a relationship with HLA class I alleles was also found in these pa-
tients [56, 298]. However, this association was not as strong as that
found with the HLA class II region [56, 298].
In keepingwith the abovementioned, it is worth noting that suscep-
tibility tomost systemic vasculitides is also essentially linked to theHLA
region [40, 290, 299, 300]. GCA, the prototype of large vessel vasculitis in
elderly people from Western countries, is firmly associated with HLA-
DRB1*04 alleles [40, 290, 299, 300]. Takayasu arteritis, another large ves-
sel vasculitis that, unlike GCA, is more common in young women from
Asian and South-American background, is predominantly related to
310 R. López-Mejías et al. / Autoimmunity Reviews 17 (2018) 301–315HLA class I alleles, in particular to HLA-B52 [40, 290]. Furthermore, AAV,
a group of small vessel vasculitides, are linked to HLA genes, specifically
with HLA-DP [40, 290].
Association with HLA class II alleles was also found in patients with
cryoglobulinemic vasculitis [301], a small vessel vasculitismainly affect-
ing the skin. This condition is rarely idiopathic and inmost cases is asso-
ciated with hepatitis C virus infection [302, 303]. Therefore, at the time
ofmaking a differential diagnosis between IgAV and vasculitis involving
small blood vessels with predominant skin symptoms, the main chal-
lenge is to differentiate it from hypersensitivity vasculitis, also called
isolated cutaneous vasculitis limited to skin, according to the new no-
menclature [21]. Clinical differences between IgAV and hypersensitivity
vasculitis are based on the lower prevalence of the latter in children, the
higher association with drug intake before the onset of the pathology
and the lesser degree of systemic involvement and disease severity in
patients with hypersensitivity vasculitis [20]. Unfortunately, there is lit-
tle information on genetic susceptibility to hypersensitivity vasculitis.
Genetic studies on this vasculitis are scarce [132] and no association of
this condition with the HLA region was confirmed, suggesting a hetero-
geneous etiology in the pathogenesis of this vasculitis that often is re-
stricted and limited to skin.
An issue of potential concern at the time of assessing the genetic role
in IgAV is that the association observed with the HLA region in
Europeans seems to be restricted to disease susceptibility. In this con-
text, no influence of HLA class I or class II genes on a specific phenotype
of the disease, in terms of disease severity or outcome, was observed by
most authors [56, 62–64]. Only two studies, performed in small series of
patients, postulated a potential association of HLA-B35 with the devel-
opment of renal damage [55, 57].
Studies on non-HLA region suggest that gene markers associated
with immune and inflammatory pathways (such as cytokines [75,
105, 106, 112–114], chemokines [136, 137, 141], adhesion molecules
[141, 147, 152, 153, 160] and T-cells [65, 227]), aberrant glycosylation
of IgA1 [234, 235], NO production [257–259], neoangiogenesis [249,
250], RAS [165, 166, 168, 181–186] as well as lipid [265], Pyrin
[268–275] and homocysteine [281, 285] metabolism may be related to
IgAV pathogenesis in different populations. It is also the case for the nu-
clear transcription factor PAX2 [209, 210]. However, these potential as-
sociations do not seem to be as strong as the influence of the HLA
region and, in most cases, they deserve further replication in larger
and independent cohorts.
Among the signals located outside the HLA region, IL18 [114], TGFB1
[75],MCP1 [141, 147] SELP [153], Agt [165, 166, 168], ACE [165, 168, 181,
182], C1GALT1 [235], NOS2A [258], eNOS [259], PON1 [265] and MEFV
[268–275] may be implicated in the predisposition to IgAV.
Regarding the severity of IgAV, IL1ß [105, 106], IL1ra [112, 113],
TGFB1 [75], IL8 [136, 137], CCL5 [141], SELP [152], Agt [165, 168], ACE
[165, 182–186], PAX2 [209, 210], CTLA4 [65, 227], MTHFR [281, 285],
C1GALT1 [234], NOS2A [258], eNOS [257, 259], VEGF [249, 250] and
MEFV [269] may be considered as markers of renal damage and/or
renal sequelae while MCP1 [147], ICAM1 [160], Agt [165] and MEFV
[268] variants may be associated with GI involvement. In addition,
MCP1 [147], Agt [165] and MEFV [268, 272, 274] may be also related to
the presence of joint symptoms.
An issue that needs to be kept inmind at the time of studying IgAV is
that most data on IgAVwere retrieved from children as this vasculitis is
typical in young people. Despite being less common, paradoxically, IgAV
is more severe in adults leading in some cases to end stage renal failure
[13]. Therefore, future studies including larger number of adults with
IgAV are required. It would be useful to determine if there are specific
gene polymorphisms influencing the susceptibility to IgAV in adults.
In line with the above, studies performed up to now did not disclose
genetic differences between IgAV in children and adults [56, 62, 64, 90,
99, 106, 136, 160, 256]. A possible explanation for that may be the rela-
tive small number of adults included in these studies. Therefore, further
assessment for potential differences between children and adults interms of disease susceptibility and, in particular, on disease severity
are needed.
Another issue to be addressed in future studies is the search for ge-
netic markers of disease severity in IgAV. So far, data looking for gene
variants associated with a more severe disease, in particular with the
risk of nephritis and renal sequelae, are promising. However, they are
based on small case-series that need replication in independent cohorts.Acknowledgements
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